GO:0071831 intermediate-density lipoprotein particle clearance: Remnant Lipoprotein Catabolism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0071831 intermediate-density lipoprotein particle clearance describes the receptor-mediated removal of intermediate-density lipoprotein (IDL) particles from the blood and degradation of their constituent parts.
• IDL is an apoB-100-containing remnant lipoprotein generated by lipolytic processing of VLDL, and its clearance determines how long atherogenic cholesterol remains in circulation.
• The major molecular players are APOB-100, APOE, LDLR, LRP1, and hepatic lipases, which together mediate hepatic and peripheral uptake of IDL.
• Impaired IDL clearance elevates remnant cholesterol and is linked to atherosclerosis, nephrotic syndrome dyslipidemia, uremic dyslipidemia, and cardiovascular risk.
• Plasma IDL concentration, particle size, and aortic lesion extent are determinants of IDL influx into the arterial intima in hyperlipidemic models.
• CRISPR knockout, point-mutation, knock-in, and overexpression cell models enable causal testing of IDL clearance genes such as APOB, APOE, LDLR, and LRP1.
Description
GO:0071831 intermediate-density lipoprotein particle clearance is the biological process in which an intermediate-density lipoprotein (IDL) particle is removed from the blood via receptor-mediated endocytosis and its constituent parts are degraded. IDL is an apoB-100-containing lipoprotein that sits between VLDL and LDL in the delipidation cascade, and its plasma residence time is a major determinant of the cholesterol burden delivered to peripheral tissues and the arterial wall. Because IDL is a remnant lipoprotein, its clearance is central to the biology of atherogenic remnant cholesterol and to the interpretation of lipid-lowering therapies that target apoB-containing particles. The process matters for researchers because it connects lipoprotein metabolism to cardiovascular disease, renal dyslipidemia, and metabolic regulation. In nephrotic syndrome, combined hyperlipidemia includes elevated VLDL, IDL, and LDL, and pravastatin treatment lowers these apoB-containing fractions. In uremic dyslipidemia, abnormal lipoprotein metabolism contributes to cardiovascular disease through altered clearance and composition of remnant particles. In genetically hyperlipidemic rabbits, the influx of LDL, IDL, and VLDL into the aortic intima depends on plasma concentration, lesion extent, and particle size, directly linking IDL clearance to atherogenesis. Mechanistically, IDL clearance requires recognition of apolipoproteins on the particle surface by hepatic receptors, internalization, and lysosomal degradation of the particle components. APOB-100 provides the structural backbone and receptor-binding determinants of IDL, while APOE can enhance receptor-mediated uptake. The LDL receptor (LDLR) and LDL receptor-related protein 1 (LRP1) are principal endocytic receptors for these particles, and their activity determines the fractional catabolic rate of apoB-containing lipoproteins. Food intake suppresses apoB secretion and fractional catabolic rates in humans, showing that IDL clearance is physiologically regulated rather than constitutive. This article integrates the QuickGO definition of GO:0071831 with verified literature to provide a research-grade overview for scientists designing CRISPR models of remnant lipoprotein clearance.
intermediate-density lipoprotein particle clearance At A Glance
| GO ID | GO:0071831 |
|---|---|
| GO term | intermediate-density lipoprotein particle clearance |
| Ontology | biological_process |
| Synonym | IDL clearance |
| Definition | The process in which a intermediate-density lipoprotein particle is removed from the blood via receptor-mediated endocytosis and its constituent parts degraded. |
| Major function | Receptor-mediated removal and degradation of IDL particles, limiting plasma residence time of atherogenic remnant cholesterol. |
| Key lipoprotein | IDL is an apoB-100-containing remnant particle derived from VLDL lipolysis. |
| Major receptors | LDLR and LRP1 mediate hepatic and peripheral uptake of apoB- and apoE-containing remnant particles. |
| Disease relevance | Impaired IDL clearance is associated with atherosclerosis, nephrotic syndrome dyslipidemia, and uremic cardiovascular disease. |
What Is GO:0071831?
In my own words, GO:0071831 intermediate-density lipoprotein particle clearance is the biological process by which an IDL particle is recognized in the bloodstream, bound by cell-surface receptors, internalized by receptor-mediated endocytosis, and then degraded along with its constituent lipids and apolipoproteins. The term is narrower than general lipoprotein clearance because it specifies the IDL particle as the substrate and requires both removal from blood and degradation of particle components.
Why Is intermediate-density lipoprotein particle clearance Important in Cell Biology?
GO:0071831 is important because the clearance rate of IDL determines how long an atherogenic apoB-containing particle remains in the circulation and how much cholesterol it can deposit in the arterial intima. In hyperlipidemic rabbits, IDL influx into the aortic intima is driven by plasma concentration, lesion extent, and particle size, which means that delayed IDL clearance directly increases atherosclerotic burden. Clinically, therapies that lower apoB-containing particles, including IDL, reduce cardiovascular risk, and emerging therapeutic targets continue to focus on apoB-containing particle metabolism. In renal disease, nephrotic syndrome and uremia produce abnormal VLDL, IDL, and LDL metabolism that contributes to cardiovascular complications. Therefore, understanding IDL clearance at the molecular level is essential for target discovery, biomarker interpretation, and the design of CRISPR-based disease models.
• IDL clearance controls the plasma residence time of atherogenic remnant cholesterol.
• IDL influx into the arterial intima is a determinant of atherosclerotic lesion development.
• Nephrotic syndrome with combined hyperlipidemia features elevated VLDL, IDL, and LDL that respond to pravastatin.
• Uremic dyslipidemia involves abnormal lipoprotein metabolism and increased cardiovascular disease.
• APOB-100 structure determines receptor-binding and clearance properties of IDL.
• APOE and LDLR/LRP1 mediate receptor-mediated endocytosis of remnant particles.
• Food intake suppresses apoB secretion and fractional catabolic rates, linking nutrition to IDL clearance.
• Remnant cholesterol, which includes IDL, is associated with clinical outcomes such as hearing loss and tinnitus in NHANES analyses.
• New and emerging therapeutic targets for apoB-containing particles depend on understanding IDL clearance.
• CRISPR models allow causal testing of candidate genes in IDL clearance pathways.
What Happens During intermediate-density lipoprotein particle clearance?
Generation and circulation of IDL particles
In simple terms: IDL is a leftover particle made when VLDL loses some of its fat.
IDL is an apoB-100-containing lipoprotein produced by lipolytic processing of VLDL, and it circulates as a remnant particle before further conversion to LDL. The structural backbone of IDL is APOB-100, which provides the framework for lipid binding and receptor recognition. Because IDL retains apoB-100 and often apoE, it can be recognized by hepatic receptors and removed from the blood. The concentration of IDL in plasma is therefore a balance between its production from VLDL and its clearance by receptor-mediated pathways.
Receptor recognition and binding
In simple terms: Receptors on liver cells grab the IDL particle.
The clearance of IDL begins with receptor recognition of apolipoproteins on the particle surface, principally APOB-100 and APOE. LDLR and LRP1 are major endocytic receptors that bind apoB- and apoE-containing remnant lipoproteins and mediate their internalization. The receptor-binding activity of APOB-100 is influenced by its conformation, which is in turn affected by lipid composition and particle size. In hyperlipidemic rabbits, particle size and plasma concentration are determinants of IDL influx into the aortic intima, reflecting the interaction between particle properties and tissue uptake.
Receptor-mediated endocytosis
In simple terms: The cell swallows the particle in a bubble.
After binding, the IDL particle is internalized by receptor-mediated endocytosis, a process in which the receptor-lipoprotein complex is taken into the cell within clathrin-coated vesicles. This step is the defining event of GO:0071831, because the QuickGO definition specifies removal from blood via receptor-mediated endocytosis. The efficiency of endocytosis determines the fractional catabolic rate of apoB-containing lipoproteins, which can be measured in human metabolic studies. Food intake suppresses apoB secretion and fractional catabolic rates, indicating that endocytic clearance is physiologically modulated.
Intracellular degradation of particle components
In simple terms: The swallowed particle is broken down inside the cell.
Following internalization, the IDL particle is delivered to lysosomes where its constituent lipids, cholesteryl esters, and apolipoproteins are degraded. The degradation step is explicitly part of the GO:0071831 definition, which requires that the constituent parts of the IDL particle be degraded. APOB-100, the major structural protein of IDL, is subject to proteolytic and lysosomal degradation after uptake. This degradation releases cholesterol and other lipids for cellular use or excretion, completing the clearance process.
Tissue distribution of IDL clearance
In simple terms: Most IDL is cleared by the liver, but some enters artery walls.
The liver is the principal site of IDL clearance because hepatocytes express high levels of LDLR and LRP1. However, in hyperlipidemic states, IDL can also enter the arterial intima, where its concentration, particle size, and the extent of aortic lesion determine its influx. This dual distribution explains why impaired IDL clearance is linked both to hepatic lipid handling and to atherosclerosis. In nephrotic syndrome and uremia, altered lipoprotein metabolism affects the clearance and composition of VLDL, IDL, and LDL, contributing to cardiovascular disease.
Key Genes Involved in GO:0071831 intermediate-density lipoprotein particle clearance
The following genes and proteins are central to IDL particle clearance, based on their roles in apoB-containing lipoprotein metabolism, receptor-mediated endocytosis, and remnant lipoprotein biology.
| Gene | Major Role | Research Relevance |
|---|---|---|
| APOB | Encodes APOB-100, the structural and receptor-binding apolipoprotein of IDL | Core target for studying IDL particle assembly and clearance |
| APOE | Apolipoprotein that enhances receptor-mediated uptake of remnant lipoproteins | Modifier of IDL and remnant clearance efficiency |
| LDLR | Primary endocytic receptor for apoB- and apoE-containing lipoproteins | Key mediator of hepatic IDL clearance |
| LRP1 | Receptor that mediates uptake of apoE-enriched remnant particles | Alternative clearance pathway for IDL |
| LIPC | Hepatic lipase involved in lipoprotein remodeling and IDL metabolism | Enzyme affecting IDL conversion and clearance |
| LPL | Lipoprotein lipase that generates IDL from VLDL | Upstream enzyme controlling IDL production |
| MTTP | Microsomal triglyceride transfer protein required for apoB lipoprotein assembly | Determines apoB particle secretion and IDL supply |
| PCSK9 | Regulates LDLR degradation and thereby IDL clearance capacity | Therapeutic target affecting remnant clearance |
| CETP | Cholesteryl ester transfer protein that remodels apoB particles | Modifies IDL lipid composition and clearance |
| ANGPTL3 | Regulator of lipoprotein lipase and remnant lipoprotein levels | Emerging target for apoB-containing particle lowering |
| APOC3 | Inhibitor of lipoprotein lipase and hepatic remnant uptake | Modulates IDL clearance and remnant cholesterol |
| SORT1 | Sortilin involved in hepatic lipoprotein secretion and clearance | Candidate modifier of apoB particle metabolism |
| ABCA1 | Cholesterol efflux transporter affecting lipoprotein composition | Indirect modifier of IDL lipid content |
| ABCG1 | Cholesterol efflux transporter in macrophage and hepatic cells | Affects lipoprotein remodeling relevant to IDL |
| SCARB1 | Scavenger receptor BI that binds HDL and apoB particles | Potential contributor to remnant lipoprotein uptake |
| NPC1L1 | Intestinal cholesterol absorption transporter | Indirectly influences apoB particle metabolism |
| INSIG1 | Regulator of SREBP and lipid synthesis | Modulates hepatic lipoprotein production |
How Is intermediate-density lipoprotein particle clearance Regulated?
IDL clearance is regulated at multiple levels. Physiologically, food intake suppresses apoB secretion and fractional catabolic rates in humans, indicating that nutritional state modulates the production and clearance of apoB-containing particles. Receptor availability is a major determinant, because LDLR levels are controlled by PCSK9-mediated degradation and by sterol-responsive transcription. Apolipoprotein composition, especially APOE content, enhances receptor binding and uptake of remnant particles. Lipolytic enzymes such as LPL and hepatic lipase determine the conversion of VLDL to IDL and the particle's subsequent clearance. In disease states such as nephrotic syndrome and uremia, altered lipoprotein metabolism changes the clearance of VLDL, IDL, and LDL, demonstrating that systemic metabolic context regulates this process. Emerging therapeutic strategies targeting apoB-containing particles further highlight the regulatory nodes that can be manipulated.
intermediate-density lipoprotein particle clearance and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| APOB | Atherogenic lipoprotein metabolism and IDL clearance | APOB knockout or point-mutation hepatocyte models |
| LDLR | Familial hypercholesterolemia and impaired remnant clearance | LDLR knockout HepG2 cells and knock-in of patient variants |
| APOE | Remnant lipoprotein clearance and cardiovascular risk | APOE isoform knock-in cell models |
| LRP1 | Hepatic remnant uptake and atherosclerosis | LRP1 knockout or tagged knock-in cells |
| PCSK9 | Regulation of LDLR and apoB particle clearance | PCSK9 overexpression and point-mutation models |
Atherosclerotic cardiovascular disease
Impaired IDL clearance increases the plasma residence time of atherogenic remnant particles and their influx into the arterial intima. In genetically hyperlipidemic rabbits, the influx of LDL, IDL, and VLDL into aortic intimas is determined by plasma concentration, extent of aortic lesion, and lipoprotein particle size, directly linking IDL clearance to atherogenesis. Remnant cholesterol, which includes IDL, has been associated with clinical outcomes such as hearing loss and tinnitus in NHANES analyses, suggesting systemic effects of remnant burden. Therapies that lower apoB-containing particles, including IDL, remain a central strategy in cardiovascular risk reduction.
Nephrotic syndrome and renal dyslipidemia
Nephrotic syndrome with hypercholesterolemia and combined hyperlipidemia features elevated VLDL, IDL, and LDL, and pravastatin treatment lowers these apoB-containing fractions. This demonstrates that IDL clearance is impaired or overwhelmed in renal disease and that pharmacological intervention can modify the process. Abnormalities in uremic lipoprotein metabolism also contribute to cardiovascular disease, with altered clearance and composition of remnant lipoproteins. These observations link GO:0071831 to kidney disease and its cardiovascular complications.
Metabolic regulation and nutrition
Food intake suppresses apoB secretion and fractional catabolic rates in humans, showing that IDL clearance is responsive to nutritional state. This regulation affects the interpretation of metabolic studies and the design of experiments that measure IDL kinetics. Because apoB-100 is the structural backbone of IDL, changes in APOB metabolism directly influence IDL clearance. Understanding these regulatory inputs is essential for modeling IDL clearance in cell and animal systems.
From intermediate-density lipoprotein particle clearance-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of APOB impair IDL clearance? | APOB knockout hepatocyte cell line |
| Does a patient LDLR variant reduce IDL uptake? | LDLR point-mutation knock-in cells |
| Does APOE isoform identity alter remnant clearance? | APOE isoform knock-in cell models |
| Where does LRP1 localize during IDL uptake? | LRP1 tagged knock-in with fluorescent tag |
| Does PCSK9 overexpression reduce IDL clearance? | PCSK9 overexpression cell model |
| Can candidate genes modify IDL clearance? | CRISPR library screening in lipoprotein-uptake reporter cells |
How to Study the intermediate-density lipoprotein particle clearance Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lipoprotein kinetic study | Fractional catabolic rate of apoB particles | In vivo assessment of IDL clearance |
| Labeled IDL uptake assay | Receptor-mediated endocytosis of IDL | Testing LDLR and LRP1 function |
| CRISPR library screen | Genes modifying lipoprotein uptake | Discovery of novel IDL clearance regulators |
| Proteomics | APOB-100, APOE, and receptor protein levels | Validation of CRISPR perturbations |
| Lipidomics | Lipid composition of IDL particles | Assessing particle remodeling |
| Immunofluorescence imaging | Cellular localization of receptors and particles | Visualizing endocytic trafficking |
| Aortic intima influx assay | Entry of IDL into arterial wall | Atherogenesis studies in hyperlipidemic models |
| ApoB secretion assay | Production of apoB-containing particles | Measuring nutritional regulation of lipoprotein metabolism |
Lipoprotein kinetic studies
Lipoprotein kinetic studies measure the fractional catabolic rate of apoB-containing particles, including IDL, and can be used to assess clearance in vivo. Food intake suppresses apoB secretion and fractional catabolic rates, so nutritional state must be controlled in these experiments. These methods provide the physiological context for cell-based CRISPR models of IDL clearance.
Receptor binding and uptake assays
Receptor binding and uptake assays using labeled IDL or apoB-containing particles can quantify LDLR- and LRP1-mediated endocytosis in cultured cells. These assays are essential for testing whether CRISPR-engineered mutations in APOB, APOE, LDLR, or LRP1 alter IDL clearance. Particle size and concentration should be controlled because they influence uptake and intimal influx.
CRISPR screening and functional genomics
CRISPR library screening can identify genes that modify IDL clearance when combined with a fluorescent or reporter-based lipoprotein uptake readout. Candidate hits can then be validated with individual knockout, point-mutation, or overexpression models. This approach is particularly useful for discovering regulators of apoB-containing particle metabolism.
Proteomics and lipidomics
Proteomics can quantify APOB-100, APOE, and receptor levels in cells and lipoprotein fractions, while lipidomics can measure the lipid composition of IDL particles. These methods help determine whether a genetic perturbation changes particle composition or clearance efficiency. They complement functional uptake assays and kinetic measurements.
How CRISPR Can Be Used to Study GO:0071831 intermediate-density lipoprotein particle clearance
Knockout
CRISPR knockout of APOB, LDLR, LRP1, or APOE in hepatocyte-derived cell lines can abolish or reduce IDL clearance and reveal the contribution of each gene to receptor-mediated endocytosis. Knockout models are also useful for validating hits from CRISPR library screens of lipoprotein uptake. Because IDL clearance requires both binding and degradation, knockout phenotypes should be assessed with uptake and degradation assays.
Point Mutation
Point-mutation knock-in of patient-derived variants in LDLR, APOB, or APOE allows researchers to test whether specific amino acid changes alter IDL binding or internalization. These models are particularly valuable for dissecting receptor-binding domains of APOB-100 and for interpreting clinical variants of uncertain significance. Point mutations can also be introduced into PCSK9 to study its regulation of LDLR and IDL clearance.
Knock-in
Knock-in of fluorescent or epitope tags into endogenous LDLR, LRP1, or APOB loci enables live-cell imaging and quantitative tracking of IDL clearance in a physiological expression context. Tagged knock-in models avoid artifacts from overexpression and allow measurement of endogenous receptor trafficking. Knock-in of human APOE isoforms can also be used to compare their effects on remnant lipoprotein clearance.
Overexpression
Overexpression of PCSK9, APOC3, or ANGPTL3 can reduce IDL clearance by promoting LDLR degradation or inhibiting lipolysis, providing gain-of-function models of impaired remnant metabolism. Conversely, overexpression of LDLR or LRP1 can enhance IDL uptake and serve as a positive control for clearance assays. Overexpression models are useful for testing therapeutic targets that modulate apoB-containing particle clearance.
How EDITGENE Supports intermediate-density lipoprotein particle clearance Research
Researchers studying intermediate-density lipoprotein particle clearance-related genes often need to determine whether a candidate gene is causally involved in IDL uptake, degradation, or plasma residence time. EDITGENE provides CRISPR-based cell models and screening services that allow precise manipulation of APOB, APOE, LDLR, LRP1, PCSK9, and other genes in the IDL clearance pathway, enabling functional validation from hypothesis to publication-ready data.
Contact EDITGENE today to design your custom CRISPR model for intermediate-density lipoprotein particle clearance research.
Frequently Asked Questions About intermediate-density lipoprotein particle clearance
What is GO:0071831 intermediate-density lipoprotein particle clearance?
GO:0071831 is the biological process in which an IDL particle is removed from the blood via receptor-mediated endocytosis and its constituent parts are degraded.
What genes are involved in intermediate-density lipoprotein particle clearance?
Key genes include APOB, APOE, LDLR, LRP1, LIPC, LPL, MTTP, PCSK9, CETP, ANGPTL3, and APOC3, based on their roles in apoB-containing lipoprotein metabolism and receptor-mediated uptake.
Which receptors mediate IDL clearance?
LDLR and LRP1 are the principal endocytic receptors that bind apoB- and apoE-containing remnant particles and mediate their internalization.
Why is IDL clearance important for cardiovascular disease?
Impaired IDL clearance increases the plasma residence time of atherogenic remnant particles and their influx into the arterial intima, contributing to atherosclerosis.
How is IDL clearance measured experimentally?
It can be measured by lipoprotein kinetic studies of fractional catabolic rate, labeled IDL uptake assays, and receptor binding experiments in cultured cells.
Does food intake affect IDL clearance?
Yes, food intake suppresses apoB secretion and fractional catabolic rates in humans, indicating nutritional regulation of apoB-containing particle clearance.
What happens to IDL after receptor-mediated endocytosis?
After internalization, the IDL particle is delivered to lysosomes where its lipids and apolipoproteins, including APOB-100, are degraded.
Is IDL clearance altered in kidney disease?
Yes, nephrotic syndrome and uremic dyslipidemia feature abnormal VLDL, IDL, and LDL metabolism, and pravastatin lowers these fractions in nephrotic hyperlipidemia.
Can CRISPR be used to study IDL clearance genes?
Yes, CRISPR knockout, point-mutation, knock-in, and overexpression models can test the causal role of APOB, APOE, LDLR, LRP1, and PCSK9 in IDL clearance.
What is the difference between IDL and LDL clearance?
IDL is an apoB-100-containing remnant particle that is cleared before conversion to LDL, and its clearance is defined separately as GO:0071831.
Conclusion
GO:0071831 intermediate-density lipoprotein particle clearance is a defined biological process that links apoB-100-containing remnant lipoprotein metabolism to receptor-mediated endocytosis and lysosomal degradation. Its molecular players, including APOB, APOE, LDLR, LRP1, and PCSK9, are well-established in the literature, and its dysfunction is associated with atherosclerosis, nephrotic syndrome dyslipidemia, and uremic cardiovascular disease. For researchers, the process offers a tractable system for CRISPR-based causal genomics. Knockout, point-mutation, knock-in, and overexpression models can be combined with lipoprotein kinetic, uptake, proteomic, and lipidomic assays to dissect IDL clearance mechanisms and to validate therapeutic targets among apoB-containing particles.
References
- 1. Devaraj S et al.. 2026. Biochemistry, Apolipoprotein B.. PMID: 30844166
- 2. Toto RD et al.. 2000. Pravastatin treatment of very low density, intermediate density and low density lipoproteins in hypercholesterolemia and combined hyperlipidemia secondary to the nephrotic syndrome.. Am J Nephrol 20(1):12-7 PMID: 10644862
- 3. Nordestgaard BG et al.. 1992. Influx in vivo of low density, intermediate density, and very low density lipoproteins into aortic intimas of genetically hyperlipidemic rabbits. Roles of plasma concentrations, extent of aortic lesion, and lipoprotein particle size as determinants.. Arterioscler Thromb 12(1):6-18 PMID: 1731859
- 4. Gaudet D et al.. 2026. New and Emerging Therapeutic Targets for ApoB-Containing Particles Lowering.. Circ Res 138(12):e327270 PMID: 42241517
- 5. Coleman B et al.. 2026. Century of Progress on the Structure of APOB-100 in Atherogenic Lipoproteins.. Circ Res 138(12):e328575 PMID: 42241510
- 6. Yin J et al.. 2026. Remnant cholesterol and auditory outcomes in NHANES 1999-2016: associations with frequency-range hearing loss and tinnitus.. Lipids Health Dis 25(1) PMID: 41820973
- 7. Quaschning T et al.. 2001. Abnormalities in uremic lipoprotein metabolism and its impact on cardiovascular disease.. Am J Kidney Dis 38(4 Suppl 1):S14-9 PMID: 11576915
- 8. Zheng C et al.. 2024. Food Intake Suppresses ApoB Secretion and Fractional Catabolic Rates in Humans.. Arterioscler Thromb Vasc Biol 44(2):435-451 PMID: 38126174
